Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

68.98 +0.25 (+0.36%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Earnings Outlook For Halozyme Therapeutics ↗

November 03, 2023

Via Benzinga

Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗

November 02, 2023

NASDAQ:HALO, a growth stock which is not overvalued.

Via Chartmill

Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune ↗

October 27, 2023

Are you looking to invest in the stock market and become a millionaire? Here are three stocks to buy to turn $1,000 into a fortune.

Via InvestorPlace

For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals. ↗

October 24, 2023

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings ↗

October 19, 2023

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or...

Via Benzinga

NASDAQ:HALO is showing decent growth, but is still valued reasonably. ↗

October 12, 2023

Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO).

Via Chartmill

Analyst Expectations for Halozyme Therapeutics's Future ↗

October 09, 2023

Via Benzinga

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

October 06, 2023

HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.

Via Chartmill

Where Halozyme Therapeutics Stands With Analysts ↗

September 08, 2023

Via Benzinga

Why NASDAQ:HALO Is a Standout High-Growth Stock in a Consolidation Phase. ↗

October 11, 2023

Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.

Via Chartmill

NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗

September 26, 2023

Is HALOZYME THERAPEUTICS INC (NASDAQ:HALO) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗

September 26, 2023

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably.

Via Chartmill

7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 23, 2023

Discover the thrill of undervalued and overlooked sleeper stocks poised for growth in a shifting market environment.

Via InvestorPlace

Expert Ratings for Halozyme Therapeutics ↗

August 15, 2023

Via Benzinga

Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗

July 28, 2023

Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.

Via Benzinga

Halozyme Therapeutics: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Halozyme Therapeutics Earnings Preview ↗

May 08, 2023

Via Benzinga

The Latest Analyst Ratings for Halozyme Therapeutics ↗

March 16, 2023

Via Benzinga

Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market ↗

July 24, 2023

HC Wainwright has initiated coverage on Halozyme Therapeutics Inc (NASDAQ: HALO) with a Buy rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗

July 24, 2023

Via Benzinga

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗

July 13, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...

Via Benzinga

5 Analysts Have This to Say About Halozyme Therapeutics ↗

February 22, 2023

Via Benzinga

Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis ↗

June 21, 2023

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 20, 2023

Via Benzinga

AI Frenzy Helps Nasdaq 100 Outshine Russell 2,000 And Soar To Dot-Com Bubble Highs ↗

May 31, 2023

The surge of artificial intelligence (AI) is sparking a transformative shift in the relative valuations of prominent U.S. stock averages as the tech sector outperforms other industries and small-cap...

Via Benzinga

7 Meme Stocks to Buy Before They Soar to New Heights in 2023 ↗

May 25, 2023

Investing in meme stocks is no longer about driving dying companies higher. In fact, let’s get into meme-worthy and investment-grade shares.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 ↗

May 10, 2023

Via Benzinga

Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme ↗

March 16, 2023

It's still unclear whether CMS will include those drugs in its negotiation list.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗

March 16, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 08, 2023

On Monday, 61 companies hit new 52-week lows.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.